INSULIN LISPRO-AABC

Insulin

Brand names: LYUMJEV

Intravenous, Subcutaneous

Mechanism of Action

12.1 Mechanism of Action The primary activity of LYUMJEV is the regulation of glucose metabolism. Insulins, including insulin lispro-aabc, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Indications

See full prescribing information

FDA Warnings

5 WARNINGS AND PRECAUTIONS Never share a LYUMJEV prefilled pen or cartridge between patients, even if the needle is changed
Monitor potassium levels in patients at risk for hypokalemia and treat if indicated
Sharing poses a risk for transmission of blood-borne pathogens
, insulin, insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions ( 5

Known Side Effects

9 documented side effects by frequency

Drug Not Working

1-10%

Nausea

1-10%

Fatigue

0.1-1%

Diarrhea

0.1-1%

Shortness of Breath

0.1-1%

General Unwellness

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

Falls

0.1-1%

Community Discussions

No community discussions found for INSULIN LISPRO-AABC yet.

Compare With

9 available comparisons

Formulations

Dosage Forms

Tablet

Route

Intravenous, Subcutaneous